Previous 10 | Next 10 |
The tech selloff so far has been brutal and quick, with 5% to 10% moves daily in high growth names across the board. On February 23rd I published a list of my picks to buy on weakness and I acted on it, in some cases it appears too early. Below I list which companies I purchased d...
AbCellera ([[ABCL]] +6.0%) announces that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly (LLY), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently di...
Patients who received bamlanivimab and etesevimab together had an 87% reduction in hospitalizations and death; no patients died who received the therapy AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCeller...
AbCellera Biologics is a little followed and largely uncovered company. What it is building however is known all throughout the biotech and pharma industries. With the likes of Bill Gates, Peter Thiel and DARPA as key backers, AbCellera is quietly creating a call option on vast swaths...
Gainers: [[SNSE]] +17.5%. [[ABCL]] +8.3%. [[AGLE]] +7.6%. [[OLED]] +5.9%. [[EOLS]] +5.4%.Losers: [[CRWD]] -7.0%. [[ARDX]] -6.9%. [[NK]] -6.6%. [[CATB]] -3.2%. [[ISEE]] -3.1%. For further details see: SNSE, AGLE, CRWD and ISEE among after-hours movers
AbCellera ([[ABCL]] -6.1%) announced that the European Medicines Agency's ((EMA)) Committee for Medicinal Products for Human Use ((CHMP)) has issued a positive recommendation for bamlanivimab alone and in combination with etesevimab for the treatment of confirmed COVID-19 in certain...
Positive European Union (EU)-level scientific opinion provides a pathway for more EU countries to access the antibodies to treat COVID-19 before formal marketing authorizations are granted AbCellera (Nasdaq: ABCL) today announced that the European Medicines Agency's (EMA) Co...
Gainers: Five Prime Therapeutics (FPRX) +78%, Ampio Pharmaceuticals (AMPE) +10%, Soligenix (SNGX) +7%.Losers: BioVie (BIVI) -29%, Schrodinger (SDGR) -25%, KemPharm (KMPH) -19%, Anchiano Therapeutics (ANCN) -15%, AbCellera Biologics (...
AbCellera (NASDAQ: ABCL) will present at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:20 p.m. Pacific Time. A live audio webcast may be accessed through a link that will be posted on AbCellera’s Investor Relations website ...
Viking Global (Andreas Halvorsen) added new positions in General Electric (GE), AbCellera Biologics (ABCL), The Walt Disney (DIS) and UnitedHealth (UNH), latest 13F filing indicates.Notable increases: Boston Scientific (BSX), Visa (V), Microsoft (MSFT), and Otis Worldwide (OTIS).The...
News, Short Squeeze, Breakout and More Instantly...
AbCellera Biologics Inc. Company Name:
ABCL Stock Symbol:
NASDAQ Market:
AbCellera Biologics Inc. Website:
AbCellera (Nasdaq: ABCL) will announce its second quarter 2024 financial results on Tuesday, August 6, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link t...
2024-06-13 05:40:00 ET Discovering new drugs can be a lucrative endeavor, but things aren't working out lately for AbCellera Biologics (NASDAQ: ABCL) . Shares of this unusual biotech stock are down by about 57% from the high water mark they set last summer. The steep losses migh...
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time). A live audio webcast of the presentation may be accessed throug...